BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20086151)

  • 1. Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones.
    Pasca MR; Degiacomi G; Ribeiro AL; Zara F; De Mori P; Heym B; Mirrione M; Brerra R; Pagani L; Pucillo L; Troupioti P; Makarov V; Cole ST; Riccardi G
    Antimicrob Agents Chemother; 2010 Apr; 54(4):1616-8. PubMed ID: 20086151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis.
    Makarov V; Manina G; Mikusova K; Möllmann U; Ryabova O; Saint-Joanis B; Dhar N; Pasca MR; Buroni S; Lucarelli AP; Milano A; De Rossi E; Belanova M; Bobovska A; Dianiskova P; Kordulakova J; Sala C; Fullam E; Schneider P; McKinney JD; Brodin P; Christophe T; Waddell S; Butcher P; Albrethsen J; Rosenkrands I; Brosch R; Nandi V; Bharath S; Gaonkar S; Shandil RK; Balasubramanian V; Balganesh T; Tyagi S; Grosset J; Riccardi G; Cole ST
    Science; 2009 May; 324(5928):801-4. PubMed ID: 19299584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of DprE1-Mediated Benzothiazinone Resistance in Mycobacterium tuberculosis.
    Foo CS; Lechartier B; Kolly GS; Boy-Röttger S; Neres J; Rybniker J; Lupien A; Sala C; Piton J; Cole ST
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6451-6459. PubMed ID: 27527085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis.
    Lechartier B; Hartkoorn RC; Cole ST
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5790-3. PubMed ID: 22926573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis.
    Makarov V; Neres J; Hartkoorn RC; Ryabova OB; Kazakova E; Šarkan M; Huszár S; Piton J; Kolly GS; Vocat A; Conroy TM; Mikušová K; Cole ST
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4446-52. PubMed ID: 25987616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decaprenylphosphoryl-β-D-ribose 2'-epimerase from Mycobacterium tuberculosis is a magic drug target.
    Manina G; Pasca MR; Buroni S; De Rossi E; Riccardi G
    Curr Med Chem; 2010; 17(27):3099-108. PubMed ID: 20629622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in
    Poulton NC; Azadian ZA; DeJesus MA; Rock JM
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0090422. PubMed ID: 35920665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-β-D-ribose 2'-epimerase DprE1 of Mycobacterium tuberculosis.
    Trefzer C; Rengifo-Gonzalez M; Hinner MJ; Schneider P; Makarov V; Cole ST; Johnsson K
    J Am Chem Soc; 2010 Oct; 132(39):13663-5. PubMed ID: 20828197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and evaluation of covalent inhibitors of DprE1 as antitubercular agents.
    Liu L; Kong C; Fumagalli M; Savková K; Xu Y; Huszár S; Sammartino JC; Fan D; Chiarelli LR; Mikušová K; Sun Z; Qiao C
    Eur J Med Chem; 2020 Dec; 208():112773. PubMed ID: 32898793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations associated with in vitro resistance to bedaquiline in Mycobacterium tuberculosis isolates in Australia.
    Martinez E; Hennessy D; Jelfs P; Crighton T; Chen SC; Sintchenko V
    Tuberculosis (Edinb); 2018 Jul; 111():31-34. PubMed ID: 30029911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antituberculars which target decaprenylphosphoryl-β-D-ribofuranose 2'-oxidase DprE1: state of art.
    Buroni S; Pasca MR; de Jesus Lopes Ribeiro AL; Degiacomi G; Molteni E; Riccardi G
    Appl Microbiol Biotechnol; 2012 May; 94(4):907-16. PubMed ID: 22526781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards a new combination therapy for tuberculosis with next generation benzothiazinones.
    Makarov V; Lechartier B; Zhang M; Neres J; van der Sar AM; Raadsen SA; Hartkoorn RC; Ryabova OB; Vocat A; Decosterd LA; Widmer N; Buclin T; Bitter W; Andries K; Pojer F; Dyson PJ; Cole ST
    EMBO Mol Med; 2014 Mar; 6(3):372-83. PubMed ID: 24500695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo antimicrobial activities of a novel piperazine-containing benzothiazinones candidate TZY-5-84 against Mycobacterium tuberculosis.
    Guo S; Fu L; Wang B; Chen X; Zhao J; Liu M; Lu Y
    Biomed Pharmacother; 2020 Nov; 131():110777. PubMed ID: 33152936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DprE1--from the discovery to the promising tuberculosis drug target.
    Mikusová K; Makarov V; Neres J
    Curr Pharm Des; 2014; 20(27):4379-403. PubMed ID: 24245764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis.
    Ribeiro AL; Degiacomi G; Ewann F; Buroni S; Incandela ML; Chiarelli LR; Mori G; Kim J; Contreras-Dominguez M; Park YS; Han SJ; Brodin P; Valentini G; Rizzi M; Riccardi G; Pasca MR
    PLoS One; 2011; 6(11):e26675. PubMed ID: 22069462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological and structural characterization of the Mycobacterium smegmatis nitroreductase NfnB, and its role in benzothiazinone resistance.
    Manina G; Bellinzoni M; Pasca MR; Neres J; Milano A; Ribeiro AL; Buroni S; Skovierová H; Dianišková P; Mikušová K; Marák J; Makarov V; Giganti D; Haouz A; Lucarelli AP; Degiacomi G; Piazza A; Chiarelli LR; De Rossi E; Salina E; Cole ST; Alzari PM; Riccardi G
    Mol Microbiol; 2010 Sep; 77(5):1172-85. PubMed ID: 20624223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-line anti-tuberculosis drug resistance and its genetic determinants in multidrug-resistant Mycobacterium tuberculosis clinical isolates.
    Bakuła Z; Napiórkowska A; Kamiński M; Augustynowicz-Kopeć E; Zwolska Z; Bielecki J; Jagielski T
    J Microbiol Immunol Infect; 2016 Jun; 49(3):439-44. PubMed ID: 26117528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis.
    Al-Mutairi NM; Ahmad S; Mokaddas E; Eldeen HS; Joseph S
    BMC Infect Dis; 2019 Jan; 19(1):3. PubMed ID: 30606116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and structure-activity relationships evaluation of benzothiazinone derivatives as potential anti-tubercular agents.
    Gao C; Ye TH; Wang NY; Zeng XX; Zhang LD; Xiong Y; You XY; Xia Y; Xu Y; Peng CT; Zuo WQ; Wei Y; Yu LT
    Bioorg Med Chem Lett; 2013 Sep; 23(17):4919-22. PubMed ID: 23886691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular detection of multidrug resistance pattern and associated gene mutations in M. tuberculosis isolates from newly diagnosed pulmonary tuberculosis patients in Addis Ababa, Ethiopia.
    Tilahun M; Shimelis E; Wogayehu T; Assefa G; Wondimagegn G; Mekonnen A; Hailu T; Bobosha K; Aseffa A
    PLoS One; 2020; 15(8):e0236054. PubMed ID: 32750053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.